Seres Therapeutics (MCRB) to Release Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is expected to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Seres Therapeutics to post earnings of ($1.88) per share and revenue of $0.4080 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.39) by $0.50. The firm had revenue of $0.44 million during the quarter.

Seres Therapeutics Stock Performance

MCRB stock opened at $7.61 on Monday. Seres Therapeutics has a one year low of $6.53 and a one year high of $29.98. The company has a fifty day moving average of $8.69 and a 200-day moving average of $13.29. The stock has a market capitalization of $73.28 million, a PE ratio of 11.53 and a beta of 0.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after buying an additional 3,918 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in shares of Seres Therapeutics in the fourth quarter valued at $190,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Seres Therapeutics during the fourth quarter valued at $214,000. Barclays PLC increased its position in Seres Therapeutics by 427.8% during the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 6,024 shares in the last quarter. Finally, State Street Corp raised its stake in Seres Therapeutics by 14.0% in the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 4,170 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on MCRB. Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a research report on Friday, March 27th. Wall Street Zen cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a research note on Friday, March 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Seres Therapeutics presently has an average rating of “Hold” and a consensus price target of $14.00.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.